BASKING RIDGE, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by
gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients Basking Ridge, NJ, January 29, 2018 – electroCore, LLC (electroCore), a commercial-stage bioelectronic medicine company, announced today that it has received 510(k) clearance from
Investment to fund commercialization of gammaCore ® and further clinical development of nVNS Basking Ridge, NJ, November 29, 2017 – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham Basking Ridge, NJ, September 11, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth Basking Ridge, NJ, August 29, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that
electroCore launches gammaCore Patient Registry (GPR) to provide access to hand-held, easy-to-use device for the acute treatment of pain associated with episodic cluster headache in adults Basking Ridge, NJ, July 18, 2017 – electroCore, a neuroscience and technology company dedicated to
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches Basking Ridge, NJ, June 15, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Data from Pooled Analysis of ACT1 and ACT2 To Be Presented in Late-Breaking Oral Session at Annual Scientific Meeting of the American Headache Society Basking Ridge, NJ, June 8, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through